SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LGTY, AZPN, ENFN on Behalf of ShareholdersNEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)BALA CYNWYD, Pa., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of ShareholdersNEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)BALA CYNWYD, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and EDBL on Behalf of ShareholdersNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of ShareholdersNEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enfusion, Inc. (
NYSEENFN) to Clearwater Analytics Holdings, Inc.
NYSE: CWANNYSECWAN)
ENFN Investors Have the Opportunity to Join Investigation of Enfusion, Inc. With the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. (“Enfusion” or “the Company”) (
NYSEENFN) for potential breaches of fiduciary duty on the part of its directors and management.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)BALA CYNWYD, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
ENFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (
NYSEENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders.
Shareholder Alert: Ademi LLP Investigates Whether Enfusion, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Ademi LLP is investigating Enfusion (
NYSEENFN) for possible breaches of fiduciary duty and other violations of law in its transaction with Clearwater.
Enfusion To Present at Upcoming Investor Events
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion’s Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events:
Enfusion Announces Third Quarter 2024 Results
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com.
Enfusion Announces Key Leadership Team Additions to Drive Client Success and Fuel Innovation
Enfusion, Inc. (“Enfusion”) (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company’s position as a global leader in investment technology and services, which enables Enfusion to continue to attract top-performing industry experts and innovators to its ranks.
Enfusion Announces Date of Third Quarter 2024 Results
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its third quarter 2024 financial results before the U.S. financial markets open on Monday, November 4, 2024. Management will host a conference call and webcast that same morning at 8:30 AM (ET) / 5:30 AM (PT) to discuss the results.
ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. (“Enfusion” or “the Company”) (
NYSEENFN) for violations of the securities laws.
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. (“Enfusion” or “the Company”) (
NYSEENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ENFN.
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. (“Enfusion” or “the Company”) (
NYSEENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ENFN.
ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. (“Enfusion” or “the Company”) (
NYSEENFN) for violations of the securities laws.
Enfusion Announces Second Quarter 2024 Results
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its second quarter 2024 financial results as part of its Q2 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com.
Enfusion Introduces the Next Phase of Portfolio Workbench, Empowering Asset Managers with Increased Efficiency and Flexibility
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the release of the next phase of Portfolio Workbench, bringing even more powerful portfolio rebalancing and construction features to users.
Enfusion Announces Date of Second Quarter 2024 Results
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its second quarter 2024 financial results before the U.S. financial markets open on Tuesday, August 6, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results.
Enfusion To Present at Upcoming Investor Events
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion’s Chief Executive Officer, Oleg Movchan, and Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events:
Enfusion Announces First Quarter 2024 Results
Enfusion, Inc. ("Enfusion") (
NYSEENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its first quarter 2024 financial results as part of its 1Q 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com.
